LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D.New post-hoc analysis of OCT scans on GCIPL and analysis of responders with improvement of 15 or 30-letter on low-contrast visual acuity (LCVA) from the Phase 2 ACUITY trial with Privosegtor, to be presented by Martin Zinkernagel, M.D., Ph.D.Corporate update on Oculis' pipeline and upcoming milestones to be presented by Riad Sherif, M.D., CEO of Oculis at Eyecelerator ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) (Oculis), a global bioph
- Schwab Marks Second Annual National Investing Day with Industry and Community Partners
Charles Schwab Foundation commits more than $20 million supporting youth financial education over the next three years Charles Schwab today kicked off the second annual National Investing Day, bringing together organizations from the financial industry and nonprofit community to participate in the day dedicated to investor education and empowerment. National Investing Day is grounded in a simple idea: while millions of Americans participate in the markets, many still lack the confidence or resources to see themselves as investors. Expanding access to credible, early education remains a critical step in closing that gap. Now in its second year, National Investing Day is building momentum
- XPENG Announces Vehicle Delivery Results for April 2026
GUANGZHOU, China, May 1, 2026 /PRNewswire/ -- XPeng Inc. ((", XPENG", or the ", Company, ", NYSE:XPEV), a leading global AI mobility technology company, today announced its vehicle delivery results for April 2026. In April, XPENG delivered a total of 31,011 vehicles, representing a 13% increase from the prior month.Furthermore, following the official rollout of VLA 2.0 in March, test-drive satisfaction rates at XPENG retail stores recorded a significant increase by the end of April. The average time customers take to make a purchase decision after a test drive also decreased by 44.7% month-over-month, reinforcing intelligent driving as a key driver of sales growth.On April 15, 2026, the Comp
- Pearson Q1 2026 Trading Update (Unaudited)
Continued execution drives good Q1 result. On track to deliver 2026 guidance. HighlightsUnderlying Group sales up 4% in Q1. All business units performing in line with expectations; continued strong performance in Virtual Learning with underlying sales up 21%, and Assessment & Qualifications expected to return to growth from Q2.On track to deliver 2026 full year guidance. Continued progress against our 2026 priorities, including: Advancing core business and enterprise power metrics, with an Enterprise strategic partnership with Salesforce and US Student Assessment contract win in Wyoming (link here). Leading with the application of innovative technologies, including the roll out of Communicat
- Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia.Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies. The ABCD PlatformTM, an evolution of Kodiak's ABC platform to include conjugation of small molecules and other drugs, continues to advance as a versatile system for targeted, multi
- NIO Inc. Provides April 2026 Delivery Update
29,356 vehicles were delivered in April 2026, increasing by 22.8% year-over-year112,821 vehicles were delivered year-to-date in 2026, increasing by 71.0% year-over-yearCumulative deliveries reached 1,110,413 as of April 30, 2026 SHANGHAI, May 01, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its April 2026 delivery results. The Company delivered 29,356 vehicles in April 2026, representing an increase of 22.8% year-over-year. The deliveries consisted of 19,024 vehicles from the Company's premium smart electric vehicle brand NIO, 5,352 vehicles from t
- Amkor Technology Prices $1,000 Million Convertible Senior Notes Offering
Amkor Technology, Inc. (NASDAQ:AMKR) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0.00% convertible senior notes due 2031 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The notes will be fully and unconditionally guaranteed, on a senior, unsecured basis, by each subsidiary of Amkor that currently or in the future guarantees its 5.875% senior notes due 2033 (the "guarantors"). The issuance and sale of the notes are scheduled to settle on May 5, 2026, subject to customary closing conditions. Amkor als
- McEwen Inc. and Golden Lake Exploration Inc. Announce Closing of Arrangement
TORONTO and VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- McEwen Inc. ("McEwen") (NYSE/TSX:MUX) and Golden Lake Exploration Inc. ("Golden Lake") (CSE:GLM) (OTCQB:GOLXF) are pleased to announce the completion of the previously announced business combination between McEwen and Golden Lake by way of statutory plan of arrangement (the "Arrangement"). Golden Lake's principal asset is its Jewel Ridge and Jewel Ridge West projects located adjacent to McEwen's Windfall and Lookout Mountain discoveries, part of the Gold Bar Mine Complex, in the Eureka Mining District of Nevada. Historical drill highlights from Jewel Ridge project include 2.20 gpt gold over 28.96 meters, 1.24 gpt
- Li Auto Inc. April 2026 Delivery Update
BEIJING, China, May 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced that it delivered 34,085 vehicles in April 2026. As of April 30, 2026, Li Auto's cumulative deliveries reached 1,669,442. In April, the all-new Li L9 Livis debuted at the 2026 Beijing International Automotive Exhibition, with its official launch scheduled for May 15. The launch event will fully showcase the vehicle's latest advancements in exterior and interior design, chassis and suspension, range extension system, safety, and intelligence. As of April 30, 2026, the Company had 511 retail stores in 160 cities,
- New insider Laurita Aaron James claimed ownership of 26,357 units of Ordinary Shares (SEC Form 3)
3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)
- Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $5.00 per share, and in lieu of common stock, to certain investors, pre-funded warrants to purchase 8,000,000 shares of common stock at a purchase price of $4.999 per pre-funded warrant share, which equals the public offering price per share of the common stock less the $0.001 exercise pr
- Amendment: Chief Executive Officer Kazley Michael John converted options into 11,361,216 shares (SEC Form 4)
4/A - Stablecoin Development Corp (0001389545) (Issuer)
- Amendment: Large owner Framework Ventures Iv L.P. converted options into 11,361,216 shares (SEC Form 4)
4/A - Stablecoin Development Corp (0001389545) (Issuer)
- Amendment: Large owner R01 Fund Lp converted options into 11,361,216 shares (SEC Form 4)
4/A - Stablecoin Development Corp (0001389545) (Issuer)
- Chief Revenue Officer Steward Ian was granted 197,090 shares, increasing direct ownership by 114% to 369,977 units (SEC Form 4)
4 - Gitlab Inc. (0001653482) (Issuer)
- SEC Form 4 filed by Chief Technology Officer Padisetty Sivaprasad
4 - Gitlab Inc. (0001653482) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Ross Jessica P
4 - Gitlab Inc. (0001653482) (Issuer)
- Chief Legal Officer & Corp Sec Schulman Robin was granted 78,836 shares, increasing direct ownership by 60% to 210,420 units (SEC Form 4)
4 - Gitlab Inc. (0001653482) (Issuer)
- Chief Executive Officer Staples William was granted 436,414 shares, increasing direct ownership by 127% to 781,065 units (SEC Form 4)
4 - Gitlab Inc. (0001653482) (Issuer)